Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: LGMD Clear all

Conditions: Limb-girdle Muscular Dystrophy, Becker Muscular Dystrophy
Interventions: Prednisone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
Interventions: AB-1003 dose level 1, AB-1003 dose level 2, Placebo; Genetic · Other
Lead sponsor: AskBio Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 6
States / cities: Irvine, California • Iowa City, Iowa • Kansas City, Kansas + 3 more

Conditions: LGMD1B, LGMD1C, LGMD1D, LGMD1E, LGMD1F, LGMD1G, LGMD1H, LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2K, LGMD2L, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2Q, LGMD2S, LGMD2T, LGMD2U, LGMD2W, LGMD2X, LGMD2Y
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 6 Years to 50 Years
Enrollment: 1,000 participants
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Katherine Mathews; Other
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 6 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: LGMD2I
Interventions: BBP-418; Drug
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions: ATYR1940; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 16 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Irvine, California • Stanford, California • Salt Lake City, Utah

Conditions: Muscular Dystrophies
Interventions: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort; Genetic
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 5 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Limb Girdle Muscular Dystrophy, Muscular Dystrophies
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 4 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: Irvine, California • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Muscular Dystrophies, Limb Girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Irvine, California • Aurora, Colorado • Gainesville, Florida + 7 more

Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Gainesville, Florida + 6 more

Conditions: Limb Girdle Muscular Dystrophy
Interventions: SRP-9003; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Columbus, Ohio • Memphis, Tennessee

Conditions: Limb Girdle Muscular Dystrophy
Interventions: SRP-6004; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Weekly Steroids in Muscular Dystrophy

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Long-Term Development of Muscular Dystrophy Outcome Assessments

Clinical Trial Readiness for the Dystroglycanopathies

Limb Girdle Muscular Dystrophy (LGMD) Natural History

Study of BBP-418 in Patients With LGMD2I

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Biomarker Development in LGMD2i

LGMD R1 Natural History Study

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)